Shots:
- Hanmi Pharm has entered into an exclusive licensing agreement with Genentech for the development, manufacturing, & commercialization of HM17321, for obesity & associated conditions such as T2D & CV diseases, globally, excl. South Korea
- As per the deal, Hanmi will receive ~$190M upfront, with additional development, regulatory & commercial milestones representing the total deal value of ~$2.3B, plus tiered royalties on future product sales following commercialization
- HM17321, a non-incretin UCN2 analog, received US FDA IND clearance in Nov 2025 & is in P-I assessing safety, tolerability, PK & PD in healthy volunteers & people with obesity. Hanmi to complete the P-I trial, with Genentech leading development from P-II
Ref: PRnewswire | Image: Hanmi & Genentech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
